What natural sleep supplements can be used to improve sleep, and what are the appropriate doses and safety considerations?

Natural Sleep Supplements: Evidence-Based Recommendations

Natural sleep supplements including melatonin, valerian, L-tryptophan, and diphenhydramine are NOT recommended for the treatment of chronic insomnia due to insufficient efficacy and safety data, according to the highest-quality clinical practice guidelines. 1, 2

Guideline-Based Position on Natural Supplements

The American Academy of Sleep Medicine's 2017 clinical practice guideline provides the most definitive stance on natural sleep supplements:

• Melatonin (2 mg): Weak recommendation AGAINST use - harms approximately equal to benefits 2
• Valerian: Weak recommendation AGAINST use - insufficient evidence despite variable dosing trials 2
• L-tryptophan (250 mg): Weak recommendation AGAINST use - very low quality evidence, harms outweigh benefits 2
• Diphenhydramine (50 mg): Weak recommendation AGAINST use - low quality evidence, harms outweigh benefits 2

The 2008 consensus guidelines from the American Academy of Sleep Medicine explicitly state that over-the-counter antihistamines and herbal/nutritional substances (including valerian and melatonin) are not recommended for chronic insomnia treatment due to relative lack of efficacy and safety data. 1

Why These Supplements Fail Clinical Standards

Melatonin

While extensively studied, meta-analyses demonstrate only small effects on sleep latency with little to no effect on wake after sleep onset (WASO) or total sleep time (TST). 1 Many trials evaluated melatonin as a chronobiotic (circadian rhythm regulator) rather than as a hypnotic, which limits applicability to insomnia treatment. One specialized context where melatonin 3 mg may be considered is in breast cancer survivors with sleep disturbance, where it improved subjective sleep quality without significant adverse effects. 3

Valerian

Available evidence shows small but inconsistent effects on sleep latency, with inconsistent effects on sleep continuity, duration, and architecture. 1 Despite being considered safe, there is no objective benefit for sleep latency or quality. 4 The 2021 perioperative guideline suggests valerian can be continued as it appears safe and may protect against cognitive dysfunction, but this does not translate to efficacy for insomnia treatment. 4

L-Tryptophan

Despite recent research suggesting ≥1 g supplementation may shorten wake after sleep onset 5, the clinical guideline evidence remains insufficient to recommend its use. The 2017 AASM guideline specifically recommends against tryptophan for sleep onset or maintenance insomnia. 2

Antihistamines (Diphenhydramine)

Evidence for efficacy and safety is very limited, with serious concerns about anticholinergic side effects. 1 These include cognitive impairment, urinary retention, constipation, and increased fall risk—particularly problematic in older adults.

What Should Be Used Instead

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

The 2016 American College of Physicians guideline establishes CBT-I as the primary treatment for chronic insomnia disorder. 6 This includes:

• Stimulus control therapy: Use bedroom only for sleep and sex; leave bedroom if unable to sleep within 15-20 minutes
• Sleep restriction: Limit time in bed to actual sleep time, then gradually increase
• Cognitive therapy: Address dysfunctional beliefs about sleep
• Sleep hygiene education: Avoid caffeine/nicotine/alcohol; maintain consistent sleep-wake times; avoid daytime napping after 2 PM or limit to 30 minutes 7

Pharmacologic Options When Necessary

When behavioral interventions are insufficient, the recommended sequence is: 1

1. Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon, temazepam) or ramelteon (melatonin receptor agonist)
2. Alternate BzRA or ramelteon if initial agent unsuccessful
3. Sedating antidepressants when comorbid depression/anxiety present (trazodone, doxepin, mirtazapine)
4. Combined therapy if needed

Critical caveat: Start at the lowest available dose, supplement with behavioral therapies when possible, and follow regularly to assess effectiveness and adverse effects. 1

Specific Prescription Recommendations from 2017 AASM Guideline

• Zolpidem 10 mg: WEAK recommendation for sleep onset and maintenance (FDA now recommends 5 mg starting dose) 2
• Temazepam 15 mg: WEAK recommendation for sleep onset and maintenance 2
• Ramelteon 8 mg: WEAK recommendation for sleep onset 2
• Doxepin 3-6 mg: WEAK recommendation for sleep maintenance 2

Special Populations and Contexts

Older Adults

Sleep hygiene and stimulus control remain foundational. 7 Pharmacologic agents should be started at the lowest dose due to increased sensitivity and fall risk. The 2009 geriatrics guideline emphasizes that benzodiazepine receptor agonists have lower frequency and severity of adverse effects compared to older benzodiazepines. 7

Emerging Research (Not Yet Guideline-Supported)

Recent 2025-2026 research suggests potential benefits from:

• L-theanine 200-450 mg/day: May improve sleep latency, maintenance, and efficiency 8, 9
• Tryptophan ≥1 g: May reduce wake after sleep onset 5
• Magnesium, vitamin D, omega-3, zinc: May enhance various sleep parameters 10

However, these findings have not been incorporated into clinical practice guidelines and should not replace evidence-based treatments.

Critical Safety Considerations

Herb-Drug Interactions

Natural supplements can cause serious interactions despite their "natural" label:

• St. John's Wort: Strong CYP3A4 inducer, increases serotonin syndrome risk, affects warfarin 4
• Valerian: Potential additive CNS depression with other sedatives 4
• Kava: Hepatotoxicity risk 11

Product Quality Concerns

Over-the-counter supplements lack FDA oversight for purity and potency. Adulteration and contamination pose real risks including hepatotoxicity, cardiovascular events, and neurological disturbances. 11

Long-Term Use Not Recommended

Efficacy and safety data for most over-the-counter insomnia medications is limited to short-term studies; their safety and efficacy in long-term treatment is unknown. 1

Practical Clinical Algorithm

1. Assess for underlying causes: Sleep apnea, restless legs syndrome, psychiatric disorders, medication effects
2. Implement sleep hygiene and stimulus control as foundation for all patients 7, 1
3. Offer CBT-I as first-line treatment (available via in-person, telephone, web-based, or self-help formats) 6
4. If pharmacotherapy needed: Start with FDA-approved agents (BzRAs or ramelteon) at lowest dose, not natural supplements 1, 2
5. Combine behavioral and pharmacologic therapy when appropriate, with regular follow-up every few weeks initially 1
6. Avoid natural supplements (melatonin, valerian, tryptophan, antihistamines) due to insufficient evidence and safety concerns 1, 2

The evidence is clear: natural sleep supplements lack the efficacy and safety data to support their use in chronic insomnia management, and evidence-based alternatives with proven benefit should be prioritized.